Table 2.

HRs for mortality comparing patients who were treated with phosphorus binders (n = 3555) with those who were untreated (n = 5055)

ParameterHR95% CIP
Intention-to-treat analysesa
    no adjustment0.580.52 to 0.66<0.0001
    multivariable-adjustedb0.700.62 to 0.79<0.0001
    vitamin D–adjustedc0.700.62 to 0.79<0.0001
    facility-specific SMR–stratifiedd0.710.62 to 0.81<0.0001
As-treated analysese
    no adjustment0.700.61 to 0.78<0.0001
    multivariable-adjustedb0.820.72 to 0.930.001
    vitamin D–adjustedc0.820.72 to 0.930.002
    facility-specific SMR–stratifiedd0.710.63 to 0.81<0.0001
  • a The treated group included patients who began treatment during the first 90 d on hemodialysis, whereas the untreated group included those who were not treated during the first 90 d.

  • b Adjusted for age; gender; race; ethnicity; cause of renal failure; systolic BP; BMI; SMR (standardized mortality rate); initial vascular access; coronary artery disease; congestive heart failure; laboratory variables including albumin, creatinine, calcium, phosphate, PTH, and hemoglobin; and vitamin D therapy at baseline.

  • c Multivariable-adjusted for all factors listed in b and time-dependent treatment with intravenous active vitamin D during the follow-up period.

  • d Multivariable-adjusted for the factors listed in b and stratified according to facility-specific SMR.

  • e Phosphorus binder therapy was modeled as a time-dependent covariate.